Targeting the PI3K Pathway in HR+/HER2- MBC

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Sara Hurvitz, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.05 MB
Released: May 31, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit

Related Content

A short slideset from Clinical Care Options covering key clinical insights for the current management of HR+/HER2- advanced breast cancer.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Slides from Neelima Denduluri, MD, FASCO: HER2-targeted TKIs and antibody-drug conjugates for HER2-positive metastatic breast cancer, from CCO

Neelima Denduluri, MD, FASCO Released: June 30, 2020

Slides from Lee Schwartzberg, MD, FACP: Optimal treatment and management of toxicities for HER2-positive early-stage breast cancer, from CCO

Lee Schwartzberg, MD, FACP Released: June 30, 2020

Slides from Sara Hurvitz, MD, FACP: Selecting CDK4/6 inhibitors and managing toxicities during treatment of HR+/HER2- advanced breast cancer, from CCO

Sara Hurvitz, MD, FACP Released: June 17, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?